BRAF and neoplasm: In addition, a proper evaluation of the preventive activity of statins towards BRAF-mutant CRC would necessitate the assessment of tumor development in the VillinCreER/0/BrafV600E-LSL/+ or other models of BRAF-driven colorectal carcinogenesis11.